BELL.L

Belluscura Plc
Belluscura PLC - Result of General Meeting
8th July 2024, 11:45
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5382V
Belluscura PLC
08 July 2024
 

8 July 2024

 

Belluscura plc

("Belluscura", the "Company"}

 

Result of General Meeting

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that at the General Meeting held earlier today both the resolutions put to the meeting were duly approved by Shareholders:

 

Resolution
(*indicates special resolution)

Votes for

% of shares voted

Votes against

% of shares voted

Resolution 1:  To allot Shares re. Loan Notes.

98,167,364

99.90%

101,411

0.10%

Resolution 2*:  To disapply Statutory
Pre-Emption Rights re. Loan Notes.

98,167,364

99.90%

101,411

0.10%

 

The Company is pleased to confirm that, as announced on 2 July 2024, following Shareholder approval for the Resolutions as they relate to the issue of the Loan Note Placing, together with the recent Share Subscriptions for new ordinary shares, the Company has raised total gross proceeds of approximately £1.92 million.

 

In accordance with the terms of the Loan Note Placing Agreement, following passing of the Resolutions, the Placing Loan Notes will be issued on 9 July 2024.

 

The net proceeds of the Loan Note Placing and Share Subscriptions will be used for working capital purposes to support the growth in both the X-PLOR® and DISCOV-RTM portable oxygen concentrator devices sales, as set out in the Announcement and the Letter to Shareholders dated 2 July 2024.

 

 

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the Announcement made by the Company at 14:30 on 2 July 2024 and the letter to Shareholders dated 2 July 2024, which constituted a supplement to the Circular dated 14 June 2024.

 

For further information please contact:

 

Belluscura plc

Tel: +44 (0)20 3128 8100

Adam Reynolds, Chairman

Robert Rauker, Chief Executive Officer

Simon Neicheril, Chief Financial Officer




SPARK Advisory Partners Limited (Nomad)

Tel: +44 (0)20 3368 3550

Neil Baldwin / Jade Bayat




Dowgate Capital Limited (Broker)

Tel: +44 (0)20 3903 7715

Russell Cook / Nicholas Chambers




MHP (Financial PR & Investor Relations)

Tel: +44 (0)20 3128 8100

Katie Hunt / Matthew Taylor 

 belluscura@mhpgroup.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMEAFXPELELEFA]]>
TwitterFacebookLinkedIn